What changed for Coeliac Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Coeliac Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 51 to 48 (-3)
- Trials on record 378 to 375 (-3)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Coeliac Disease yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Coeliac Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05574010 · results posted 10 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05574010) tested a drug called KAN-101 in people with coeliac disease. The trial was run in three parts (A, B, and C) and enrolled a total of 128 participants across ten groups, receiving either different doses of KAN-101 (0.6, 1.2, or 3.0 mg per kilogram of body weight) or a placebo (a dummy treatment with no active ingredient). Part A looked at unwanted medical events (called adverse events) that occurred after dosing. Parts B and C measured changes in a blood protein called IL-2 — a substance that tends to rise in peopl...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06001177 · results posted 18 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 55 people in total — 28 received a treatment called KAN-101 (at a dose of 0.6 mg/kg) and 27 received a placebo (a dummy treatment with no active ingredient). All participants had coeliac disease. The trial was measuring how the gut lining responded after participants were deliberately exposed to gluten for two weeks — a process called a "gluten challenge." The main thing researchers were tracking was a ratio called villous height to crypt depth (Vh:Cd), which is a way of measuring the tiny finger-like structures in th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04424927 · results posted 20 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04424927) tested a drug called PRV-015 in people with coeliac disease. The trial ran in two stages: first, all 388 participants took a placebo (a dummy treatment with no active ingredient) for four weeks — 352 of them completed this stage. Then, 226 of those participants moved into a 24-week double-blind stage, where they were randomly assigned to receive either a placebo or one of three doses of PRV-015 (100 mg, 300 mg, or 600 mg), with roughly 56–57 people in each group. Neither the participants nor the researchers knew...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04604795 · results posted 9 May 2023
According to the results reported on ClinicalTrials.gov, this trial studied a drug called GSK3915393 and was conducted in three separate parts (A, B, and C). Part A involved 12 participants split across four small groups of 3, who each received different combinations of the drug, a placebo (a dummy treatment with no active ingredient), or an intravenous (drip) dose across multiple treatment periods. Part B enrolled 38 participants split into four groups — one placebo group and three groups receiving different doses of GSK3915393 taken by mouth, over up to 14 days. Part C involved 12 participan...
-
NCT03866538 · results posted 26 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03866538) was designed to compare two groups of people with coeliac disease who were taking a medicine called budesonide — one group would keep taking it, and the other would stop. The trial aimed to measure changes in the lining of the small bowel (using a camera procedure with tissue samples), as well as changes in symptoms, quality of life, body weight, iron levels, and vitamin D levels. In total, only one participant was recorded as having started and completed the trial, and no participants were recorded in the "Conti...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04227197 · results posted 14 June 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04227197) enrolled 230 people in total — 117 in the intervention group and 113 in the control group. The trial was looking at care for children and young people with Down syndrome, and was measuring whether a support tool (described as "Down Syndrome Clinic to You") helped families and their regular doctors follow through on five health checks recommended by national guidelines for Down syndrome: a coeliac screen, a sleep study, a thyroid test, a hearing test, and an eye assessment. Caregivers and doctors were surveyed at...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00931892 · results posted 4 June 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 adults in total — 10 in a "low gluten" group and 10 in a "high gluten" group. All 20 completed the gluten challenge phase and the first two rounds of gut tissue sampling (endoscopies). In the third endoscopy, one person in the high gluten group did not complete it, leaving 9 in that group at the final stage. The trial was measuring what happens to the lining of the small bowel — and to certain immune and symptom markers — when people with coeliac disease are exposed to different amounts of gluten over a short perio...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03738475 · results posted 12 August 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03738475) enrolled 34 adults in total — 16 received a treatment called TIMP-GLIA at a dose of 8 mg/kg, and 18 received a placebo (a dummy treatment). One person in the TIMP-GLIA group did not complete the trial; everyone in the placebo group finished. The trial was designed to measure how the immune system responded to gluten (a protein found in wheat and related grains) in people with coeliac disease, looking at changes in certain immune cells and intestinal tissue after a period of deliberate gluten exposure. The report...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02633020 · results posted 27 December 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02633020) looked at a treatment called AMG 714 in people with refractory coeliac disease type 2 — a rare and serious form of coeliac disease that does not respond to a gluten-free diet. A total of 28 people took part: 19 received AMG 714 and 9 received a placebo (a dummy treatment with no active ingredient). The trial was mainly measuring changes in a type of abnormal white blood cell found in the gut lining, called aberrant intraepithelial lymphocytes, which are a key feature of this condition. Several other measures were...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02637141 · results posted 3 December 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 64 people in total across three groups: 22 received a lower dose of the investigational drug AMG 714 (150 mg), 22 received a higher dose (300 mg), and 20 received a placebo (an inactive treatment). All participants had coeliac disease and were deliberately exposed to gluten during the study — a method used to observe how the small intestine responds. The trial was primarily measuring changes in the structure of the small intestine lining, specifically a ratio comparing the height of tiny nutrient-absorbing projections...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01439035 · results posted 26 September 2018
According to the results reported on ClinicalTrials.gov, this was a small pilot trial (registered as NCT01439035) that enrolled 6 participants, all of whom completed the study. The trial was testing a medical imaging technique called Optical Frequency Domain Imaging (OFDI) — a type of detailed internal camera scan — to see whether it could detect changes in the tiny finger-like projections lining the small intestine (called villi) that are associated with coeliac disease. The researchers compared what the OFDI scan showed against standard tissue samples (biopsies) taken during the same procedu...
-
NCT01787825 · results posted 10 May 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 121 people in total — 60 starting with one capsule camera device (CapsoCam SV-1) before crossing over to the other (PillCam SB2), and 61 doing it in the reverse order. This was a crossover study, meaning every participant used both swallowable camera capsules, which are small pill-sized devices that take pictures as they travel through the small bowel (the middle part of the digestive system). The trial was comparing the two devices by looking at whether the images they each captured led reviewers to the same conclusi...
-
NCT01661933 · results posted 13 October 2014
According to the results reported on ClinicalTrials.gov, this trial involved 12 participants, all of whom had been infected with a small number of *Necator americanus* hookworms and then exposed to increasing amounts of gluten over time. The trial was broken into three stages — a tiny gluten exposure, a low-dose gluten challenge, and a high-dose gluten challenge — with all 12 participants completing the first stage, 10 completing the second, and 8 completing the third. The study was primarily measuring whether the lining of the small bowel (the gut's inner wall) stayed intact during gluten exp...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research investment is currently directed toward Coeliac Disease, and that level has remained broadly steady over recent years. For patients, this suggests the condition holds a consistent place on the research agenda rather than experiencing sharp rises or falls in scientific attention. Steady funding often means ongoing work continues in...
See the full Coeliac Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.